Wedbush analyst David Nierengarten maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price target of ...
EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback